Details for Patent: 5,242,901
✉ Email this page to a colleague
Summary for Patent: 5,242,901
Title: | Reduction of anthracycline induced cardiotoxicity |
Abstract: | Disclosed is a method for preventing cardiotoxicity in a human in need of such preventive treatment, the method including administering an effective amount of a bisdioxopiperazine. Also disclosed is a method for preventing cardiotoxicity induced by the administration of an anthracycline. Further, a tumoricidal, cardioprotective combination of agents is disclosed. |
Inventor(s): | Speyer; James L. (New York, NY), Muggia; Franco M. (Los Angeles, CA), Green; Michael D. (North Carlton, AU) |
Assignee: | New York University (New York, NY) |
Application Number: | 07/860,581 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 5,242,901
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,242,901
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 1337590 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |